Test your basic knowledge |

USMLE Step 1 Immunology

Instructions:
  • Answer 50 questions in 15 minutes.
  • If you are not ready to take this test, you can study here.
  • Match each statement with the correct term.
  • Don't refresh. All questions and answers are randomly picked and ordered every time you load a test.

This is a study tool. The 3 wrong answers for each question are randomly chosen from answers to other questions. So, you might find at times the answers obvious, but you will see it re-enforces your understanding as you take the test each time.
1. What are the two signals required for B cell class switching? Which is the second signal?






2. what mediates the type II hypersensitivity? What are the two different methods?






3. Which cytokines do Th2 release and For what?






4. What do mature naive B lymphocytes express?






5. For which toxins are preformed antibodies (passive) given?






6. What are the sinusoids of the spleen? What is the difference between a spleen and a lymph node?






7. What is recomb alpha interferon used for?






8. What is the end result of complement activation? what bugs are this important for? through what pathway and why?






9. What are the autoantibodies for pernicious anemia?






10. What cytokines are released by Th1 cells?






11. which of the IL2 inhibitors produce nephrotoxicity? thrombocytopenia/leukopenia?






12. Which type of selection of thymic development provides central tolerance?






13. What can cause a lymph node enlargement?






14. What is an example of a parasite showing antigenic variation?






15. what results in symptoms of shock in an acute hemolytic transfusion reaction?






16. What are the mediators that mast cells release?






17. What is the clinical use of Muromonab?






18. What are the autoantibodies for goodpastures syndrome?






19. What is the most common example of passive immunity?






20. How do you test for type III hypersensitivity?






21. What is the cause of thymic aplasia? What is its presentation? What are the labs?






22. What are the main Cell surface proteins on T cells?






23. explain the process from beginning (ie phagocytosis of the peptide) to end of how Abs are formed in Goodpasteurs.






24. What is anergy? why does this occur?






25. Which TCR MHC system is important for viral immunity? neoplastic? donor graft cells?






26. What is the white pulp of the spleen?






27. Which disease is associated with DR7?






28. What are complements in the complement system? What activates them? there seems to be different ones - What are these pathways called?






29. Name 5 ways Antibody diversity is generated?






30. What is recomb gamma interferon used for?






31. What is the main cytokine that activates eosinophils?






32. If the alternative pathway is constitively active - how come normal cells don't get attacked with MAC?






33. in which immunodef order do you see a lot of pus? no pus?






34. The pathogenesis of contact dermatitis is ________ hypersensitivity






35. What does granulysin do?






36. What are superantigens? give two examples.






37. What lymph node drains the rectum (above the pectinate line)?






38. How do we use thymus dependent antigens to prevent infection from organisms that lack a peptide component?






39. What is the pathogenesis of chronic granulomatous disease; What is the presentation? What is the labs?






40. after C3 spontaneously hydrolyzes to C3b and C3a - what happens to C3a?






41. Describe the Mannose Lectin pathway






42. Which disease is associated with HLA A3?






43. which type of immunity is slow but long lasting? as opposed to...






44. What are the autoantibodies for wegeners granulomatosis?






45. which of the hypersensitivity reactions is not Ab mediated?






46. How does igA cross the epithelium?






47. can igG cross the placenta?






48. Name the three opsonins






49. which of the transplant rejections is antibody mediated? why does it occur?






50. What is the toxicity of muromonab?